BPH progression: Concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE

Research output: Contribution to journalReview articlepeer-review

161 Scopus citations


Benign prostatic hyperplasia (BPH) represents a significant burden in ageing men due to frequently associated lower urinary tract symptoms (LUTS), which may impair quality of life. BPH is also a progressive disease, mainly characterized by a deterioration of LUTS over time, and in some patients by the occurrence of serious outcomes such as acute urinary retention (AUR) and need for BPH-related surgery. The goals of therapy for BPH are not only to improve bothersome LUTS but also to identify those patients at risk of unfavourable outcomes, to optimize their management. In selected patients, combination of an α1-blocker and a 5α-reductase inhibitor is the most effective form of BPH medical therapy to reduce the risk of clinical progression and relieve LUTS. Monotherapy also significantly reduces the risk of BPH clinical progression, mainly through a reduction of LUTS deterioration for α1-blockers while 5α-reductase inhibitors also reduce the risk of AUR and need for BPH-related surgery. Enlarged prostate and high serum prostate-specific antigen levels have been consistently found to be good clinical predictors of AUR and BPH-related surgery in longitudinal population-based studies and placebo arms of controlled studies. High post-void residual urine (PVR) is also associated with an increased risk of LUTS deterioration and should thus be reconsidered in practice as a predictor of BPH progression. Conversely, baseline LUTS severity and low peak flow rate, initially identified as predictors of unfavourable outcomes in community setting, behave paradoxically in controlled trials, probably as a consequence of strict inclusion criteria and subsequent regression to the mean and glass ceiling effects. Lastly, there is increasing evidence that dynamic variables, such as LUTS and PVR worsening, and lack of symptomatic improvement with α1-blockers are important predictors of future LUTS/BPH-related events, allowing better identification and management of patients at risk of BPH progression.

Original languageEnglish (US)
Pages (from-to)17-21
Number of pages5
JournalBJU International, Supplement
Issue numberSUPPL. 3
StatePublished - Mar 2008


  • 5α-reductase inhibitors
  • Acute urinary retention
  • Alfuzosin
  • Benign prostatic hyperplasia
  • LUTS
  • α-blockers

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'BPH progression: Concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE'. Together they form a unique fingerprint.

Cite this